The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Sodium–glucose cotransporter 2 inhibitors vs. sitagliptin in heart failure and type 2 diabetes: an observational cohort study
Abstract
Aims: The effectiveness of sodium–glucose cotransporter 2 inhibitors (SGLT2i) in patients with heart failure (HF) in routine clinical practice is not extensively studied. This study aimed to evaluate the comparative effectiveness of SGLT2i vs. sitagliptin in older adults with HF and type 2 diabetes and to investigate whether there were any differences between agents within the SGLT2i class or for reduced and preserved ejection fraction. Methods and results: Using Medicare claims data (April 2013 to December 2019), 16 253 SGLT2i initiators vs. 43 352 initiators of sitagliptin aged ≥65 years with type 2 diabetes and HF were included. The primary outcome was a composite of all-cause mortality, hospitalization for HF or urgent visit requiring intravenous diuretics; secondary outcomes included its individual components. Propensity score fine stratification weighted Cox regression was used to adjust for 100 pre-exposure characteristics. Mean age was 74 years; 49.8% were women. Initiation of SGLT2i vs. sitagliptin was associated with a lower risk of the primary composite outcome [adjusted hazard ratio (HR) 0.72; 95% confidence interval 0.67–0.77]. The adjusted HRs were 0.70 (0.63–0.78) for all-cause mortality, 0.64 (0.58–0.70) for hospitalization for HF, and 0.77 (0.69–0.86) for urgent visit requiring intravenous diuretics. Similar associations with the primary composite outcome were observed for all three agents within the SGLT2i class, for reduced and preserved ejection fraction, and subgroups based on demographics, comorbidities, and other HF treatments. Bias-calibrated HRs for the primary endpoint using negative and positive control outcomes ranged between 0.81 and 0.89, suggesting that the observed benefit could not be fully explained by residual confounding. Conclusion: In routine US clinical practice, SGLT2i demonstrated robust clinical effectiveness in older adults with HF and type 2 diabetes compared with sitagliptin, with no evidence of heterogeneity across the SGLT2i class or across ejection fraction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The comparator, sitagliptin, served as a placebo proxy regarding the outcome of interest as it showed no effect on heart failure events in a major randomized clinical trial and previously successfully served as a placebo proxy in claims data analyses.15,18,19”
From Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction (2025) · cites this paper as [18]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Dapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618
Cardiovascular and renal outcomes with empagliflozin in heart failure
Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., Januzzi, J., Verma, S., Tsutsui, H., Brueckmann, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022190 · Cited by 5,206
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Circulation · doi:10.1161/cir.0000000000001063 · Cited by 4,922
Empagliflozin in heart failure with a preserved ejection fraction
Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Bocchi, E., Böhm, M., Brunner–La Rocca, H.-P., Choi, D.-J., Chopra, V., Chuquiure-Valenzuela, E., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107038 · Cited by 4,874
Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
Solomon, S. D., McMurray, J. J. V., Claggett, B., de Boer, R. A., DeMets, D., Hernandez, A. F., Inzucchi, S. E., Kosiborod, M. N., Lam, C. S. P., Martinez, F., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206286 · Cited by 2,884
Self-citationEffect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Green, J. B., Bethel, M. A., Armstrong, P. W., Buse, J. B., Engel, S. S., Garg, J., Josse, R., Kaufman, K. D., Koglin, J., Korn, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501352 · Cited by 2,577
Sotagliflozin in patients with diabetes and recent worsening heart failure
Bhatt, D. L., Szarek, M., Steg, P. G., Cannon, C. P., Leiter, L. A., McGuire, D. K., Lewis, J. B., Riddle, M. C., Voors, A. A., Metra, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2030183 · Cited by 1,868
Sattar, N., Lee, M. M. Y., Kristensen, S. L., Branch, K. R. H., Del Prato, S., Khurmi, N. S., Lam, C. S. P., Lopes, R. D., McMurray, J. J. V., Pratley, R. E., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00203-5 · Cited by 1,599
Triangulation in aetiological epidemiology
Lawlor, D. A., Tilling, K., & Davey Smith, G. (2017) · International Journal of Epidemiology · doi:10.1093/ije/dyw314 · Cited by 1,129
Research works printed but not linked: 45
- Bertoni, 2004, Heart failure prevalence, incidence, and mortality in the elderly with diabetes, Diabetes Care, 27, 699, 10.2337/diacare.27.3.699 · DOI · Paper page
- Savarese, 2017, Global Public Health Burden of Heart Failure, Card Fail Rev, 3, 7, 10.15420/cfr.2016:25:2 · DOI · Paper page
- Tsao, 2018, Temporal trends in the incidence of and mortality associated with heart failure with preserved and reduced ejection fraction, JACC Heart Fail, 6, 678, 10.1016/j.jchf.2018.03.006 · DOI · Paper page
- Owan, 2006, Trends in prevalence and outcome of heart failure with preserved ejection fraction, N Engl J Med, 355, 251, 10.1056/NEJMoa052256 · DOI · Paper page
- Dunlay, 2017, Epidemiology of heart failure with preserved ejection fraction, Nat Rev Cardiol, 14, 591, 10.1038/nrcardio.2017.65 · DOI · Paper page
- Steinberg, 2012, Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes, Circulation, 126, 65, 10.1161/CIRCULATIONAHA.111.080770 · DOI · Paper page
- McMurray, 2019, Dapagliflozin in patients with heart failure and reduced ejection fraction, N Engl J Med, 381, 1995, 10.1056/NEJMoa1911303 · DOI · Paper page
- McDonagh, 2021, 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure, Eur Heart J, 42, 3599, 10.1093/eurheartj/ehab368 · DOI · Paper page
- Packer, 2021, Effect of empagliflozin on worsening heart failure events in patients with heart failure and preserved ejection fraction: EMPEROR-Preserved trial, Circulation, 144, 1284, 10.1161/CIRCULATIONAHA.121.056824 · DOI · Paper page
- Schneeweiss, 2019, Graphical depiction of longitudinal study designs in health care databases, Ann Intern Med, 170, 398, 10.7326/M18-3079 · DOI · Paper page
- American Diabetes Association, 2017, 8. Pharmacologic approaches to glycemic treatment, Diabetes Care, 40, S64, 10.2337/dc17-S011 · DOI · Paper page
- American Diabetes Association, 2018, 8. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2018, Diabetes Care, 41, S73, 10.2337/dc18-S008 · DOI · Paper page
- Scirica, 2013, Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus, N Engl J Med, 369, 1317, 10.1056/NEJMoa1307684 · DOI · Paper page
- Toh, 2016, Risk for hospitalized heart failure among new users of saxagliptin, sitagliptin, and other antihyperglycemic drugs: a retrospective cohort study, Ann Intern Med, 164, 705, 10.7326/M15-2568 · DOI · Paper page
- Filion, 2016, A multicenter observational study of incretin-based drugs and heart failure, N Engl J Med, 374, 1145, 10.1056/NEJMoa1506115 · DOI · Paper page
- Gallwitz, 2013, Safety and efficacy of linagliptin in type 2 diabetes patients with common renal and cardiovascular risk factors, Ther Adv Endocrinol Metab, 4, 95, 10.1177/2042018813486165 · DOI · Paper page
- Patorno, 2018, Preferential prescribing and utilization trends of diabetes medications among patients with renal impairment: emerging role of linagliptin and other dipeptidyl peptidase 4 inhibitors, Endocrinol Diabetes Metab, 1, e00005, 10.1002/edm2.5 · DOI · Paper page
- Desai, 2020, Bias implications of outcome misclassification in observational studies evaluating association between treatments and all-cause or cardiovascular mortality using administrative claims, J Am Heart Assoc, 9, 10.1161/JAHA.120.016906 · DOI · Paper page
- Desai, 2021, Effectiveness of angiotensin-neprilysin inhibitor treatment versus renin-angiotensin system blockade in older adults with heart failure in clinical care, Heart, 107, 1407, 10.1136/heartjnl-2021-319405 · DOI
- Patorno, 2019, Empagliflozin and the risk of heart failure hospitalization in routine clinical care, Circulation, 139, 2822, 10.1161/CIRCULATIONAHA.118.039177 · DOI · Paper page
- Desai, 2022, Comparative effectiveness of empagliflozin in reducing the burden of recurrent cardiovascular hospitalizations among older adults with diabetes in routine clinical care, Am Heart J, 254, 203, 10.1016/j.ahj.2022.09.008 · DOI
- Kim, 2018, Measuring frailty in Medicare data: development and validation of a claims-based frailty index, J Gerontol A Biol Sci Med Sci, 73, 980, 10.1093/gerona/glx229 · DOI · Paper page
- Desai, 2017, A propensity-score-based fine stratification approach for confounding adjustment when exposure is infrequent, Epidemiology, 28, 249, 10.1097/EDE.0000000000000595 · DOI · Paper page
- Fu, 2019, Merits and caveats of propensity scores to adjust for confounding, Nephrol Dial Transplant, 34, 1629, 10.1093/ndt/gfy283 · DOI
- Austin, 2009, Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research, Commun Stat Simul Comput, 38, 1228, 10.1080/03610910902859574 · DOI · Paper page
- Austin, 2009, Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples, Stat Med, 28, 3083, 10.1002/sim.3697 · DOI · Paper page
- Franklin, 2014, Metrics for covariate balance in cohort studies of causal effects, Stat Med, 33, 1685, 10.1002/sim.6058 · DOI · Paper page
- Putter, 2007, Tutorial in biostatistics: competing risks and multi-state models, Stat Med, 26, 2389, 10.1002/sim.2712 · DOI · Paper page
- Masri, 2017, Limitations of administrative data for studying patients hospitalized with heart failure, Ann Intern Med, 166, 916, 10.7326/L17-0077 · doi:10.7326/l17-0077
- Desai, 2018, Development and preliminary validation of a Medicare claims-based model to predict left ventricular ejection fraction class in patients with heart failure, Circ Cardiovasc Qual Outcomes, 11, 10.1161/CIRCOUTCOMES.118.004700 · DOI
- Mahesri, 2021, External validation of a claims-based model to predict left ventricular ejection fraction class in patients with heart failure, PLoS One, 16, 10.1371/journal.pone.0252903 · doi:10.1371/journal.pone.0252903
- Shi, 2020, A selective review of negative control methods in epidemiology, Curr Epidemiol Rep, 7, 190, 10.1007/s40471-020-00243-4 · DOI · Paper page
- Fu, 2021, Pharmacoepidemiology for nephrologists (part 2): potential biases and how to overcome them, Clin Kidney J, 14, 1317, 10.1093/ckj/sfaa242 · DOI
- Arnold, 2016, Brief report: negative controls to detect selection bias and measurement bias in epidemiologic studies, Epidemiology, 27, 637, 10.1097/EDE.0000000000000504 · DOI
- Neal, 2017, Canagliflozin and cardiovascular and renal events in type 2 diabetes, N Engl J Med, 377, 644, 10.1056/NEJMoa1611925 · DOI · Paper page
- Butler, 2022, Early benefit with empagliflozin in heart failure with preserved ejection fraction: insights from the EMPEROR-Preserved trial, Eur J Heart Fail, 24, 245, 10.1002/ejhf.2420 · DOI
- Johansen, 2020, The cardiovascular outcomes, heart failure and kidney disease trials tell that the time to use sodium–glucose cotransporter 2 inhibitors is now, Clin Cardiol, 43, 1376, 10.1002/clc.23508 · DOI
- Becher, 2021, Use of sodium–glucose co-transporter 2 inhibitors in patients with heart failure and type 2 diabetes mellitus: data from the Swedish Heart Failure Registry, Eur J Heart Fail, 23, 1012, 10.1002/ejhf.2131 · DOI
- Lam, 2021, Association of sodium–glucose cotransporter-2 inhibitors with outcomes in type 2 diabetes with reduced and preserved left ventricular ejection fraction: analysis from the CVD-REAL 2 study, Diabetes Obes Metab, 23, 1431, 10.1111/dom.14356 · DOI
- Packer, 2018, Do DPP-4 inhibitors cause heart failure events by promoting adrenergically mediated cardiotoxicity? Clues from laboratory models and clinical trials, Circ Res, 122, 928, 10.1161/CIRCRESAHA.118.312673 · DOI
- Chu, 2011, CXCR4 Antagonism attenuates the cardiorenal consequences of mineralocorticoid excess, Circ Heart Fail, 4, 651, 10.1161/CIRCHEARTFAILURE.110.960831 · DOI
- Jackson, 2018, National burden of heart failure events in the United States, 2006 to 2014, Circ Heart Fail, 11, 10.1161/CIRCHEARTFAILURE.117.004873 · DOI · Paper page
- Desai, 2021, Epidemiologic characterization of heart failure with reduced or preserved ejection fraction populations identified using Medicare claims, Am J Med, 134, e241, 10.1016/j.amjmed.2020.09.038 · DOI
- Zou, 2022, Sodium–glucose cotransporter-2 inhibitors in patients with heart failure: a systematic review and meta-analysis, Ann Intern Med, 175, 851, 10.7326/M21-4284 · DOI
- Quin, 2017, Concordance between administrative data and clinical review for mortality in the randomized on/off bypass follow-up study (ROOBY-FS), J Card Surg, 32, 751, 10.1111/jocs.13379 · DOI
Cited by
Shin, A., Koo, B. K., Lee, J. Y., & Kang, E. H. (2024) · BMJ · doi:10.1136/bmj-2024-079475 · Cited by 69
Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction
Krüger, N., Schneeweiss, S., Fuse, K., Matseyko, S., Sreedhara, S. K., Hahn, G., Schunkert, H., & Wang, S. V. (2025) · JAMA · doi:10.1001/jama.2025.14092 · Cited by 66
Metadata
- Authors
- Fu, E. L., Patorno, E., Everett, B. M., Vaduganathan, M., Solomon, S. D., Levin, R., Schneeweiss, S., & Desai, R. J.
- Affiliations
- Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School , 1620 Tremont St., BC-3030, Boston, MA 02120 , USA
- Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School , Boston , USA
- ORCID
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2023-06-01
- Volume
- 44
- Issue
- 24
- Pages
- 2216-2230
- ISSN
- 0195-668X
- 1522-9645
- Cited by
- 30
- References
- 18
- Language
- en
- Funders
- Netherlands Organization for Scientific Research
- PCORI (#DB-2020C2–20326, K08AG055670)
- National Institute on Aging
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Sodium–glucose cotransporter 2 inhibitors vs. sitagliptin in heart failure and type 2 diabetes: an observational cohort study. https://app.cochat.ai/papers/10.1093/eurheartj/ehad273
- The paper
- Fu, E. L., Patorno, E., Everett, B. M., Vaduganathan, M., Solomon, S. D., Levin, R., Schneeweiss, S., & Desai, R. J. (2023). Sodium–glucose cotransporter 2 inhibitors vs. sitagliptin in heart failure and type 2 diabetes: an observational cohort study. European Heart Journal. https://doi.org/10.1093/eurheartj/ehad273
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.